Abstract:The current coronavirus disease 2019 (COVID-19) pandemic that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a significant threat to public health. Although vaccines based on the mRNA of the SARS-CoV-2 spike protein have been developed to induce both cellular and humoral immunity against SARS-CoV-2, there have been some concerns raised about their high cost, particularly in developing countries. In the present study, we aim to identify an immunogenic peptide in the SARS-CoV-2 spike protein to activate cellular immunity, particularly CD4+ helper T lymphocytes (Th cells), which are a commander of immune system. SARS-CoV-2 spike protein-derived peptides Spike448-477 and Spike489-513(N501Y)-specific CD4+ Th cell lines were generated by repetitive stimulation of healthy donor-derived CD4+T-cells with each peptide. Their HLA-restrictions were addressed by using blocking antibodies against HLA and HLA-transfected L-cells. The epitopes of Spike448-477-specific CD4+ Th cell lines were defined using a series of 7-14-mer overlapping truncated peptides and alanine-substituted epitope peptides. To address responsiveness of these CD4+ Th cell lines to several SARS-CoV-2 variants, we stimulated the CD4+ Th cell lines with mutated peptides. We addressed whether these identified peptides were useful for monitoring T-cell-based immune responses in vaccinated donors using the IFN-γ ELISpot assay. The Spike448-477 peptide was found to be a promiscuous peptide presented by HLA- DRB1*08:02, DR53, and DPB1*02:02. Although HLA-DPB1*02:02-restricted CD4+ Th cells did not response to some peptides with the L452R and L452Q mutations, the other CD4+ Th cells were not affected by any mutant peptides. We developed two tetramers to detect HLA-DRB1*08:02/Spike449-463- and Spike449-463(L452R/Y453F)-recognizing CD4+ Th cells. Spike489-513(N501Y) peptide was also a promiscuously presented to HLA-DRB1*09:01 and DRB1*15:02. The T-cell responses specific to both peptides Spike448-477 and Spike489-513 were detected in PBMCs after vaccinations. In addition, we observed that the Spike448-477 peptide activated both CD8+ T-cells and CD4+ Th cells in individuals receiving mRNA vaccines. SARS-CoV-2 spike protein-derived peptides, Spike448-477 and Spike489-513, include several epitopes that are presented by multiple HLA-class II alleles to activate CD4+ Th cells, which are considered useful for monitoring the establishment of acquired immunity after vaccination.

Yeast display of MHC-II enables rapid identification of peptide ligands from protein antigens (RIPPA)

Rapid Identification of CD4+ T-cell Epitopes Using Yeast Displaying Pathogen-Derived Peptide Library.

Identification of Human T Cell Receptor Γδ-Recognized Epitopes/Proteins Via CDR3δ Peptide-based Immunobiochemical Strategy

Use of Baculovirus MHC/peptide Display Libraries to Characterize T‐cell Receptor Ligands

Construction and Screening of an Antigen-Derived Peptide Library Displayed on Yeast Cell Surface for CD4+ T Cell Epitope Identification

Cell Surface Display of Functional Human MHC Class II Proteins: Yeast Display Versus Insect Cell Display.

Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries

Identification of virus epitopes and reactive T-cell receptors from memory T cells without peptide synthesis

High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation

Directed Evolution of Soluble Single-chain Human Class II MHC Molecules

A general platform for targeting MHC-II antigens via a single loop

Identification and relative abundance of naturally presented and cross-reactive influenza A virus MHC class I-restricted T cell epitopes

Effective assessment of CD4 T cell Immunodominance patterns: impact of antigen processing and HLA restriction

Strategy for Identifying Dendritic Cell-Processed CD4+ T Cell Epitopes from the HIV Gag P24 Protein

De novo identification of CD4 + T cell epitopes

Impact of peptide:HLA complex stability for the identification of SARS-CoV-2-specific CD8+T cells

Validation of novel conditional ligands and large-scale detection of antigen-specific T cells for H-2Dd and H-2Kd

Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics

CD4+ T cell epitope identification de novo

Deciphering CD4+ T cell specificity using novel MHC–TCR chimeric receptors

SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity